Compare ILMN & VEEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | VEEV |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6B | 27.4B |
| IPO Year | 2000 | 2013 |
| Metric | ILMN | VEEV |
|---|---|---|
| Price | $164.78 | $162.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 25 |
| Target Price | $124.24 | ★ $280.42 |
| AVG Volume (30 Days) | 1.8M | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.87 | 25.93 |
| EPS | 0.87 | ★ 1.57 |
| Revenue | ★ $4,343,000,000.00 | $1,104,081,000.00 |
| Revenue This Year | $6.47 | $14.42 |
| Revenue Next Year | $5.58 | $12.17 |
| P/E Ratio | $190.79 | ★ $103.08 |
| Revenue Growth | N/A | ★ 28.05 |
| 52 Week Low | $86.03 | $148.05 |
| 52 Week High | $177.22 | $310.50 |
| Indicator | ILMN | VEEV |
|---|---|---|
| Relative Strength Index (RSI) | 67.14 | 44.49 |
| Support Level | $116.54 | $152.04 |
| Resistance Level | $177.22 | $173.34 |
| Average True Range (ATR) | 6.66 | 7.87 |
| MACD | 0.04 | -1.11 |
| Stochastic Oscillator | 70.77 | 19.45 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.